G	O
(	O
Anh	O
)	O
MTetra	O
,	O
a	O
natural	O
bacterial	O
cell	O
wall	O
breakdown	O
product	O
,	O
induces	O
interleukin-1	B-protein
beta	I-protein
and	O
interleukin-6	B-protein
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

A	O
study	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
inflammatory	B-protein
cytokine	I-protein
expression	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1994	O
Jun	O
17	O
;	O
269	O
(	O
24	O
)	O
:	O
16983	O
]	O

It	O
is	O
believed	O
that	O
induction	O
of	O
cytokine	B-protein
expression	O
by	O
bacterial	O
cell	O
wall	O
components	O
plays	O
a	O
role	O
in	O
the	O
development	O
and	O
course	O
of	O
sepsis	O
.	O

However	O
,	O
most	O
attention	O
has	O
been	O
focused	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

We	O
studied	O
the	O
ability	O
of	O
N-acetylglucosaminyl-1	O
,	O
6-anhydro-N-acetylmuramyl-L-alanyl-D-	O
isoglutamyl-m-diaminopimelyl-D-alanine	O
(	O
G	O
(	O
Anh	O
)	O
MTetra	O
)	O
,	O
a	O
naturally	O
occurring	O
breakdown	O
product	O
of	O
peptidoglycan	O
that	O
is	O
produced	O
by	O
soluble	O
lytic	B-protein
transglycosylase	I-protein
of	O
Escherichia	O
coli	O
,	O
to	O
induce	O
cytokine	B-protein
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
.	O

G	O
(	O
Anh	O
)	O
MTetra	O
was	O
found	O
to	O
strongly	O
induce	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-1	I-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
after	O
2	O
h	O
and	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-protein
protein	I-protein
secretion	O
after	O
48	O
h	O
of	O
activation	O
.	O

The	O
increase	O
in	O
mRNA	O
accumulation	O
was	O
at	O
least	O
partly	O
due	O
to	O
an	O
increase	O
in	O
the	O
transcription	O
rates	O
of	O
the	O
respective	O
genes	B-DNA
and	O
was	O
accompanied	O
by	O
a	O
strong	O
induction	O
of	O
nuclear	O
factor-kappa	O
B	O
and	O
activator	O
protein-1	O
transcription	O
factor	O
expression	O
.	O

Experiments	O
using	O
inhibitors	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
,	O
protein	B-protein
kinase	I-protein
A	I-protein
,	O
and	O
tyrosine	O
kinase-dependent	O
pathways	O
revealed	O
that	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
involves	O
activation	O
of	O
an	O
H7-inhibitable	O
pathway	O
.	O

By	O
using	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
,	O
it	O
was	O
shown	O
that	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
depends	O
on	O
the	O
synthesis	O
of	O
new	O
protein	O
,	O
whereas	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	I-protein
mRNA	O
accumulation	O
does	O
not	O
.	O

When	O
responses	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
were	O
compared	O
with	O
those	O
to	O
LPS	O
and	O
muramyldipeptide	O
(	O
MDP	O
)	O
,	O
it	O
was	O
found	O
that	O
the	O
optimal	O
response	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
induction	O
was	O
similar	O
to	O
that	O
of	O
LPS	O
but	O
significantly	O
higher	O
than	O
the	O
response	O
to	O
MDP	O
.	O

Furthermore	O
,	O
maximal	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-RNA
mRNA	I-RNA
expression	O
could	O
be	O
enhanced	O
by	O
co-stimulation	O
with	O
LPS	O
or	O
MDP	O
,	O
suggesting	O
that	O
different	O
receptors	O
and/or	O
transduction	O
pathways	O
were	O
involved	O
.	O

These	O
results	O
indicate	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
induces	O
IL-1	B-protein
beta	I-protein
and	O
IL-6	B-protein
expression	O
in	O
human	B-cell_type
monocytes	I-cell_type
suggesting	O
a	O
possible	O
role	O
for	O
G	O
(	O
Anh	O
)	O
MTetra	O
in	O
the	O
release	O
of	O
cytokines	B-protein
during	O
sepsis	O
.	O

Te®	NULL
Journat	NULL
or	NULL
Brorocicat	NULL
Ciemistry	NULL
©	NULL
1994	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

269	NULL
,	NULL
No	NULL
.	NULL

6	NULL
,	NULL
Issue	NULL
of	NULL
February	NULL
11	NULL
,	NULL
pp	NULL
.	NULL

4201-4206	NULL
,	NULL
1994	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
,	NULL
a	NULL
Natural	NULL
Bacterial	NULL
Cell	NULL
Wall	NULL
Breakdown	NULL
Product	NULL
,	NULL
Induces	NULL
Interleukin-1	NULL
$	NULL
and	NULL
Interleukin-6	NULL
Expression	NULL
in	NULL
Human	NULL
Monocytes	NULL
A	NULL
STUDY	NULL
OF	NULL
THE	NULL
MOLECULAR	NULL
MECHANISMS	NULL
INVOLVED	NULL
IN	NULL
INFLAMMATORY	NULL
CYTOKINE	NULL
EXPRESSION*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
July	NULL
14	NULL
,	NULL
1993	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
October	NULL
14	NULL
,	NULL
1993	NULL
)	NULL
Willem	NULL
H.	NULL
A.	NULL
Doktert	NULL
,	NULL
Arnoud	NULL
J.	NULL
Sicco	NULL
B.	NULL
Koopmans	NULL
}	NULL
,	NULL
Ben	NULL
K.	NULL
Stulpt	NULL
}	NULL
,	NULL
Wolfgang	NULL
Kecks§	NULL
,	NULL
M.	NULL
Ruud	NULL
Haliet	NULL
,	NULL
and	NULL
Edo	NULL
Vellenga+f1	NULL
From	NULL
the	NULL
{	NULL
Division	NULL
of	NULL
Hematology	NULL
,	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
Groningen	NULL
,	NULL
9713	NULL
EZ	NULL
Groningen	NULL
,	NULL
The	NULL
Netherlands	NULL
and	NULL
§Pharma	NULL
Research	NULL
Department	NULL
,	NULL
Hoffmann-La	NULL
Roche	NULL
Ltd.	NULL
,	NULL
Basel	NULL
CH-4002	NULL
,	NULL
Switzerland	NULL
It	NULL
is	NULL
believed	NULL
that	NULL
induction	NULL
of	NULL
cytokine	NULL
expression	NULL
by	NULL
bacterial	NULL
cell	NULL
wall	NULL
components	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
development	NULL
and	NULL
course	NULL
of	NULL
sepsis	NULL
.	NULL

However	NULL
,	NULL
most	NULL
attention	NULL
has	NULL
been	NULL
focused	NULL
on	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
.	NULL

We	NULL
studied	NULL
the	NULL
ability	NULL
of	NULL
N-acetylglucosaminyl-1,6-anhydro-N-acetyImuramyl-r-alanyl-v-isoglutamyl-m-diaminopime-	NULL
Tetra	NULL
)	NULL
,	NULL
a	NULL
naturally	NULL
occurring	NULL
breakdown	NULL
product	NULL
of	NULL
peptidoglycan	NULL
that	NULL
is	NULL
produced	NULL
by	NULL
soluble	NULL
lytic	NULL
transglycosylase	NULL
of	NULL
Escherichia	NULL
coli	NULL
,	NULL
to	NULL
induce	NULL
cytokine	NULL
expression	NULL
in	NULL
human	NULL
monocytes	NULL
.	NULL

G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
was	NULL
found	NULL
to	NULL
strongly	NULL
induce	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-18	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
after	NULL
2	NULL
h	NULL
and	NULL
IL-1	NULL
8	NULL
and	NULL
IL-6	NULL
protein	NULL
secretion	NULL
after	NULL
48	NULL
h	NULL
of	NULL
activation	NULL
.	NULL

The	NULL
increase	NULL
in	NULL
mRNA	NULL
accumulation	NULL
was	NULL
at	NULL
least	NULL
partly	NULL
due	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
transcription	NULL
rates	NULL
of	NULL
the	NULL
respective	NULL
genes	NULL
and	NULL
was	NULL
accompanied	NULL
by	NULL
a	NULL
strong	NULL
induction	NULL
of	NULL
nuclear	NULL
factor-	NULL
«	NULL
B	NULL
and	NULL
activator	NULL
protein-1	NULL
transcription	NULL
factor	NULL
expression	NULL
.	NULL

Experiments	NULL
using	NULL
inhibitors	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
,	NULL
protein	NULL
kinase	NULL
A	NULL
,	NULL
and	NULL
tyrosine	NULL
kinase-dependent	NULL
pathways	NULL
revealed	NULL
that	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-1	NULL
$	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
involves	NULL
activation	NULL
of	NULL
an	NULL
H7-inhibitable	NULL
pathway	NULL
.	NULL

By	NULL
using	NULL
the	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
cycloheximide	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
depends	NULL
on	NULL
the	NULL
synthesis	NULL
of	NULL
new	NULL
protein	NULL
,	NULL
whereas	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-18	NULL
mRNA	NULL
accumulation	NULL
does	NULL
not	NULL
.	NULL

When	NULL
responses	NULL
to	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
were	NULL
compared	NULL
with	NULL
those	NULL
to	NULL
LPS	NULL
and	NULL
muramyldipeptide	NULL
(	NULL
MDP	NULL
)	NULL
,	NULL
it	NULL
was	NULL
found	NULL
that	NULL
the	NULL
optimal	NULL
response	NULL
to	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
induction	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
LPS	NULL
but	NULL
significantly	NULL
higher	NULL
than	NULL
the	NULL
response	NULL
to	NULL
MDP	NULL
.	NULL

Furthermore	NULL
,	NULL
maximal	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-16	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
could	NULL
be	NULL
enhanced	NULL
by	NULL
co-stimulation	NULL
with	NULL
LPS	NULL
or	NULL
MDP	NULL
,	NULL
suggesting	NULL
that	NULL
different	NULL
receptors	NULL
and/or	NULL
transduction	NULL
pathways	NULL
were	NULL
involved	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
Tetra	NULL
induces	NULL
IL-1	NULL
$	NULL
6	NULL
and	NULL
IL-6	NULL
expression	NULL
in	NULL
human	NULL
monocytes	NULL
suggesting	NULL
a	NULL
possible	NULL
role	NULL
for	NULL
Tetra	NULL
in	NULL
the	NULL
release	NULL
of	NULL
cytokines	NULL
during	NULL
sepsis	NULL
.	NULL

Certain	NULL
components	NULL
of	NULL
the	NULL
bacterial	NULL
cell	NULL
wall	NULL
are	NULL
known	NULL
to	NULL
activate	NULL
several	NULL
blood	NULL
cells	NULL
like	NULL
T-cells	NULL
and	NULL
monocytes	NULL
.	NULL

They	NULL
are	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
the	NULL
Jan	NULL
Kornelis	NULL
de	NULL
Cock	NULL
Stichting	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

1	NULL
A	NULL
fellow	NULL
of	NULL
the	NULL
Royal	NULL
Netherlands	NULL
Academy	NULL
of	NULL
Arts	NULL
and	NULL
Sciences	NULL
.	NULL

To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Dept	NULL
.	NULL

of	NULL
Hematology	NULL
,	NULL
University	NULL
Hospital	NULL
,	NULL
Oostersingel	NULL
59	NULL
,	NULL
9713	NULL
EZ	NULL
Groningen	NULL
,	NULL
The	NULL
Nether-lands	NULL
.	NULL

Fax	NULL
:	NULL
31-50-633113.	NULL
thought	NULL
to	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
course	NULL
of	NULL
a	NULL
bacterial	NULL
infection	NULL
that	NULL
leads	NULL
to	NULL
sepsis	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
monocytes	NULL
by	NULL
certain	NULL
bacterial	NULL
cell	NULL
wall	NULL
components	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
lead	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
inflammatory	NULL
cytokines	NULL
that	NULL
are	NULL
known	NULL
to	NULL
be	NULL
important	NULL
determinants	NULL
of	NULL
sepsis	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Of	NULL
the	NULL
active	NULL
cell	NULL
wall	NULL
components	NULL
,	NULL
the	NULL
lipopolysaccharides	NULL
(	NULL
LPS	NULL
,	NULL
endotoxins	NULL
)	NULL
of	NULL
Gram-negative	NULL
bacteria	NULL
have	NULL
been	NULL
the	NULL
most	NULL
extensively	NULL
stud-ied	NULL
.	NULL

LPS	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
powerful	NULL
inducers	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
inflammatory	NULL
cytokines	NULL
IL-1	NULL
$	NULL
,	NULL
11-6	NULL
,	NULL
and	NULL
TNFa	NULL
from	NULL
human	NULL
blood	NULL
monocytes	NULL
.	NULL

However	NULL
,	NULL
although	NULL
LPS	NULL
are	NULL
likely	NULL
to	NULL
be	NULL
a	NULL
very	NULL
important	NULL
mediator	NULL
of	NULL
sepsis	NULL
(	NULL
3	NULL
)	NULL
,	NULL
other	NULL
factors	NULL
must	NULL
also	NULL
be	NULL
involved	NULL
.	NULL

This	NULL
is	NULL
demonstrated	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
Gram-positive	NULL
bacteria	NULL
,	NULL
which	NULL
do	NULL
not	NULL
contain	NULL
LPS	NULL
in	NULL
their	NULL
cell	NULL
walls	NULL
,	NULL
are	NULL
also	NULL
capable	NULL
of	NULL
causing	NULL
septic	NULL
shock	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
LPS-insensitive	NULL
mice	NULL
remain	NULL
vulnerable	NULL
to	NULL
Gram-negative	NULL
sepsis	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Other	NULL
bacterial	NULL
cell	NULL
wall	NULL
components	NULL
that	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
inducers	NULL
of	NULL
cytokines	NULL
and	NULL
consequently	NULL
might	NULL
be	NULL
important	NULL
during	NULL
the	NULL
development	NULL
of	NULL
sepsis	NULL
are	NULL
the	NULL
teichoic	NULL
acids	NULL
,	NULL
lipoprotein	NULL
,	NULL
staphylococcal	NULL
protein	NULL
A	NULL
and	NULL
peptidoglycan	NULL
(	NULL
5-9	NULL
)	NULL
.	NULL

Peptidoglycan	NULL
has	NULL
long	NULL
been	NULL
recognized	NULL
to	NULL
possess	NULL
immuno-stimulatory	NULL
properties	NULL
.	NULL

Although	NULL
some	NULL
studies	NULL
on	NULL
cytokine	NULL
induction	NULL
by	NULL
soluble	NULL
forms	NULL
of	NULL
peptidoglycan	NULL
(	NULL
10	NULL
)	NULL
have	NULL
been	NULL
re-ported	NULL
,	NULL
most	NULL
attention	NULL
has	NULL
been	NULL
focused	NULL
on	NULL
the	NULL
synthetic	NULL
muramylpeptide	NULL
_	NULL
N-acetyl-muramyl-t-alanyl-v-isoglutamine	NULL
(	NULL
MDP	NULL
)	NULL
,	NULL
the	NULL
smallest	NULL
common	NULL
structural	NULL
unit	NULL
of	NULL
adjuvant	NULL
pep-tidoglycans	NULL
(	NULL
11	NULL
)	NULL
.	NULL

MDP	NULL
and	NULL
lipophilic	NULL
MDP	NULL
derivatives	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
induce	NULL
the	NULL
expression	NULL
of	NULL
IL-1	NULL
,	NULL
IL-6	NULL
,	NULL
G-CSF	NULL
,	NULL
M-CSF	NULL
,	NULL
PGE2	NULL
,	NULL
TNFa	NULL
,	NULL
and	NULL
IFN-y	NULL
and	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
stimulate	NULL
host	NULL
defense	NULL
activities	NULL
against	NULL
bacterial	NULL
infections	NULL
in	NULL
vivo	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Although	NULL
MDP	NULL
might	NULL
be	NULL
a	NULL
very	NULL
interesting	NULL
tool	NULL
for	NULL
stimulating	NULL
host	NULL
defense	NULL
,	NULL
it	NULL
is	NULL
not	NULL
a	NULL
naturally	NULL
occuring	NULL
muramylpep-tide	NULL
.	NULL

It	NULL
is	NULL
not	NULL
a	NULL
product	NULL
of	NULL
bacterial	NULL
peptidoglycan-degrading	NULL
enzymes	NULL
nor	NULL
has	NULL
it	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
produced	NULL
after	NULL
phagocy-tosis	NULL
by	NULL
macrophages	NULL
(	NULL
13	NULL
,	NULL
14	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
results	NULL
of	NULL
these	NULL
studies	NULL
do	NULL
not	NULL
indicate	NULL
a	NULL
physiological	NULL
role	NULL
of	NULL
peptidoglycan	NULL
breakdown	NULL
products	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
expression	NULL
of	NULL
inflammatory	NULL
cytokines	NULL
during	NULL
the	NULL
development	NULL
of	NULL
sepsis	NULL
.	NULL

To	NULL
study	NULL
the	NULL
ability	NULL
of	NULL
peptidoglycan	NULL
breakdown	NULL
products	NULL
of	NULL
bacteria	NULL
during	NULL
infection	NULL
and	NULL
to	NULL
induce	NULL
cytokine	NULL
expression	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
response	NULL
of	NULL
human	NULL
monocytes	NULL
to	NULL
exposure	NULL
to	NULL
a	NULL
disaccharide-tetrapeptide	NULL
:	NULL
N-acetylglucosaminyl-1,6-anhydro-	NULL
'	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
LPS	NULL
,	NULL
lipopolysaccharide	NULL
(	NULL
s	NULL
)	NULL
;	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
,	NULL
N-acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl-L-alanyl-v-isoglutamyl-m-diaminopimelyl-v-alanine	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
MDP	NULL
,	NULL
mur-amyldipeptide	NULL
;	NULL
CHX	NULL
,	NULL
cycloheximide	NULL
;	NULL
kb	NULL
,	NULL
kilobase	NULL
(	NULL
s	NULL
)	NULL
;	NULL
AP-1	NULL
,	NULL
activator	NULL
protein-1	NULL
;	NULL
NF-IL6	NULL
,	NULL
nuclear	NULL
factor	NULL
IL-6	NULL
;	NULL
NK-	NULL
«	NULL
B	NULL
,	NULL
nuclear	NULL
factor-	NULL
«	NULL
B	NULL
.	NULL

4201	NULL
4202	NULL
alanine	NULL
Tetra	NULL
)	NULL
.	NULL

G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
is	NULL
structurally	NULL
similar	NULL
to	NULL
the	NULL
muramylpeptides	NULL
produced	NULL
by	NULL
lysozyme	NULL
but	NULL
possesses	NULL
an	NULL
internal	NULL
1,6-anhydro	NULL
bond	NULL
within	NULL
the	NULL
muramic	NULL
acid	NULL
residue	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

It	NULL
is	NULL
produced	NULL
by	NULL
the	NULL
soluble	NULL
lytic	NULL
transglycosylases	NULL
of	NULL
Escherichia	NULL
coli	NULL
(	NULL
15	NULL
,	NULL
17	NULL
)	NULL
and	NULL
also	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
released	NULL
during	NULL
normal	NULL
growth	NULL
by	NULL
Neisseria	NULL
gonorrhoeae	NULL
(	NULL
18	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
identical	NULL
to	NULL
tracheal	NULL
cytotoxin	NULL
of	NULL
Bordetella	NULL
pertussis	NULL
(	NULL
20	NULL
)	NULL
and	NULL
to	NULL
the	NULL
uri-nary-sleep	NULL
inducing	NULL
factor	NULL
(	NULL
21-23	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
1,6-anhydro	NULL
structure	NULL
of	NULL
Tetra	NULL
greatly	NULL
enhanced	NULL
potency	NULL
for	NULL
promoting	NULL
slow	NULL
wave	NULL
sleep	NULL
in	NULL
rabbits	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Since	NULL
Dinarello	NULL
and	NULL
Krueger	NULL
(	NULL
25	NULL
)	NULL
demonstrated	NULL
that	NULL
Tetra	NULL
induces	NULL
IL-1	NULL
expression	NULL
in	NULL
human	NULL
mononuclear	NULL
cells	NULL
in	NULL
vitro	NULL
,	NULL
it	NULL
is	NULL
believed	NULL
that	NULL
some	NULL
activities	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
are	NULL
mediated	NULL
through	NULL
IL-1	NULL
.	NULL

However	NULL
,	NULL
up	NULL
to	NULL
now	NULL
it	NULL
has	NULL
been	NULL
difficult	NULL
to	NULL
obtain	NULL
quantities	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
large	NULL
enough	NULL
to	NULL
study	NULL
its	NULL
effect	NULL
on	NULL
he-matopoietic	NULL
cells	NULL
in	NULL
detail	NULL
(	NULL
22	NULL
,	NULL
23	NULL
)	NULL
.	NULL

To	NULL
obtain	NULL
large	NULL
amounts	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
,	NULL
we	NULL
made	NULL
use	NULL
of	NULL
a	NULL
recently	NULL
described	NULL
method	NULL
for	NULL
large	NULL
scale	NULL
purification	NULL
of	NULL
G	NULL
{	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
,	NULL
using	NULL
immobilized	NULL
murein	NULL
hydrolases	NULL
from	NULL
£	NULL
.	NULL

coli	NULL
fused	NULL
to	NULL
staphylococcal	NULL
protein	NULL
A	NULL
(	NULL
16	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
demonstrate	NULL
that	NULL
Tetra	NULL
strongly	NULL
induces	NULL
IL-18	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
in	NULL
human	NULL
monocytes	NULL
.	NULL

The	NULL
extent	NULL
of	NULL
induction	NULL
of	NULL
IL-18	NULL
and	NULL
IL-6	NULL
mRNA	NULL
by	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
and	NULL
by	NULL
LPS	NULL
was	NULL
similar	NULL
but	NULL
significantly	NULL
stronger	NULL
than	NULL
by	NULL
MDP	NULL
.	NULL

The	NULL
data	NULL
suggest	NULL
a	NULL
possible	NULL
role	NULL
for	NULL
Tetra	NULL
in	NULL
the	NULL
development	NULL
of	NULL
sepsis	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Preparation	NULL
of	NULL
Cells-Peripheral	NULL
blood	NULL
cells	NULL
were	NULL
obtained	NULL
from	NULL
volunteer	NULL
platelet	NULL
donors	NULL
,	NULL
and	NULL
mononuclear	NULL
cell	NULL
suspensions	NULL
were	NULL
prepared	NULL
by	NULL
Ficoll-Hypaque	NULL
density	NULL
gradient	NULL
centrifugation	NULL
.	NULL

T	NULL
lymphocytes	NULL
were	NULL
removed	NULL
by	NULL
2-aminoethylisothiouronium	NULL
bromide-treated	NULL
sheep	NULL
red	NULL
blood	NULL
cell	NULL
rosetting	NULL
.	NULL

Monocytes	NULL
were	NULL
further	NULL
enriched	NULL
by	NULL
plastic	NULL
adherence	NULL
(	NULL
1	NULL
h	NULL
,	NULL
37	NULL
°C	NULL
)	NULL
to	NULL
a	NULL
purity	NULL
>	NULL
95	NULL
%	NULL
,	NULL
as	NULL
detected	NULL
by	NULL
fluores-cence-activated	NULL
cell	NULL
sorting	NULL
analysis	NULL
with	NULL
CD-14	NULL
(	NULL
Beckton-Dickinson	NULL
,	NULL
Sunnyville	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Monocytes	NULL
were	NULL
cultured	NULL
at	NULL
a	NULL
density	NULL
of	NULL
1-2	NULL
x	NULL
10	NULL
%	NULL
/ml	NULL
in	NULL
RPMI	NULL
1640	NULL
media	NULL
(	NULL
Flow	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
supplemented	NULL
with	NULL
100	NULL
units/ml	NULL
penicillin	NULL
,	NULL
100	NULL
pg/ml	NULL
streptomycin	NULL
,	NULL
2	NULL
mm	NULL
L-glutamine	NULL
,	NULL
and	NULL
6	NULL
ng/ml	NULL
colistin	NULL
.	NULL

Isolation	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
was	NULL
enzymatically	NULL
prepared	NULL
by	NULL
using	NULL
immobilized	NULL
murein	NULL
hydrolases	NULL
from	NULL
E.	NULL
coli	NULL
fused	NULL
to	NULL
staphylococcal	NULL
protein	NULL
A	NULL
as	NULL
described	NULL
(	NULL
16	NULL
)	NULL
.	NULL

The	NULL
structure	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
is	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Tetra	NULL
was	NULL
free	NULL
of	NULL
endotoxin	NULL
as	NULL
measured	NULL
by	NULL
a	NULL
chromogenic	NULL
limulus	NULL
amoebocyte	NULL
lysate	NULL
assay	NULL
as	NULL
described	NULL
(	NULL
26	NULL
)	NULL
.	NULL

Purity	NULL
of	NULL
the	NULL
preparation	NULL
was	NULL
determined	NULL
using	NULL
high	NULL
pressure	NULL
liquid	NULL
chromatography	NULL
analysis	NULL
as	NULL
described	NULL
(	NULL
16	NULL
)	NULL
and	NULL
was	NULL
90	NULL
%	NULL
.	NULL

The	NULL
other	NULL
10	NULL
%	NULL
consisted	NULL
of	NULL
1,6-anhydro-muramyl	NULL
peptides	NULL
with	NULL
a	NULL
different	NULL
peptide	NULL
moiety	NULL
(	NULL
16	NULL
)	NULL
.	NULL

The	NULL
concentration	NULL
was	NULL
determined	NULL
using	NULL
amino	NULL
acid	NULL
analysis	NULL
after	NULL
acid	NULL
hydrolyzation	NULL
and	NULL
ortho-phtaldialdehyde	NULL
derivatization	NULL
on	NULL
a	NULL
Hewlett	NULL
Packard	NULL
analyzer	NULL
.	NULL

Stimulation-Before	NULL
activation	NULL
,	NULL
cells	NULL
were	NULL
kept	NULL
in	NULL
the	NULL
described	NULL
medium	NULL
for	NULL
16	NULL
h.	NULL
Subsequently	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
for	NULL
various	NULL
time	NULL
periods	NULL
with	NULL
1.25	NULL
ug/ml	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
.	NULL

H7	NULL
(	NULL
Calbiochem	NULL
)	NULL
was	NULL
used	NULL
at	NULL
50	NULL
um	NULL
,	NULL
H8	NULL
(	NULL
Calbiochem	NULL
)	NULL
was	NULL
used	NULL
at	NULL
1.2	NULL
um	NULL
,	NULL
genistein	NULL
(	NULL
Sigma	NULL
)	NULL
was	NULL
used	NULL
at	NULL
20	NULL
ug/ml	NULL
(	NULL
27	NULL
,	NULL
28	NULL
)	NULL
,	NULL
and	NULL
cycloheximide	NULL
(	NULL
CHX	NULL
;	NULL
Sigma	NULL
)	NULL
was	NULL
used	NULL
at	NULL
10	NULL
ug/ml	NULL
.	NULL

LPS	NULL
(	NULL
E.	NULL
coli	NULL
,	NULL
serotype	NULL
055	NULL
:	NULL
B5	NULL
)	NULL
and	NULL
MDP	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
.	NULL

Polyclonal	NULL
anti-serum	NULL
against	NULL
IL-1a	NULL
and	NULL
IL-18	NULL
(	NULL
gift	NULL
from	NULL
Dr.	NULL
S.	NULL
Gillis	NULL
,	NULL
Immunex	NULL
,	NULL
Seattle	NULL
,	NULL
WA	NULL
)	NULL
was	NULL
used	NULL
at	NULL
a	NULL
dilution	NULL
of	NULL
1:1000	NULL
.	NULL

These	NULL
concentrations	NULL
completely	NULL
neutralize	NULL
the	NULL
activity	NULL
of	NULL
IL-la	NULL
and	NULL
IL-18	NULL
(	NULL
200	NULL
units/ml	NULL
)	NULL
tested	NULL
in	NULL
in	NULL
vitro	NULL
culture	NULL
assay	NULL
.	NULL

mRNA	NULL
Extraction	NULL
and	NULL
Analysis-Total	NULL
cellular	NULL
RNA	NULL
was	NULL
isolated	NULL
,	NULL
and	NULL
IL-18	NULL
and	NULL
IL-6	NULL
mRNA	NULL
levels	NULL
were	NULL
analyzed	NULL
by	NULL
Northern	NULL
analysis	NULL
as	NULL
described	NULL
(	NULL
29	NULL
)	NULL
by	NULL
using	NULL
a	NULL
0.3-kb	NULL
*°P-labeled	NULL
IL-6	NULL
cDNA	NULL
probe	NULL
(	NULL
30	NULL
)	NULL
(	NULL
gift	NULL
from	NULL
Dr.	NULL
L.	NULL
Aarden	NULL
,	NULL
Amsterdam	NULL
,	NULL
The	NULL
Netherlands	NULL
)	NULL
or	NULL
a	NULL
0.6-kb	NULL
IL-1B	NULL
cDNA	NULL
probe	NULL
(	NULL
gift	NULL
from	NULL
Dr.	NULL
S.	NULL
Gillis	NULL
)	NULL
.	NULL

Quantification	NULL
of	NULL
mRNA	NULL
levels	NULL
was	NULL
performed	NULL
by	NULL
densitometric	NULL
scanning	NULL
using	NULL
a	NULL
Gel	NULL
Scan	NULL
laser	NULL
densitom-eter	NULL
(	NULL
Pharmacia	NULL
LKB	NULL
Biotechnology	NULL
Inc.	NULL
)	NULL
.	NULL

IL-6	NULL
and	NULL
IL-1B	NULL
Secretion-1	NULL
x	NULL
10°	NULL
monocytes	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
during	NULL
48	NULL
h	NULL
or	NULL
in	NULL
medium	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
(	NULL
1.25	NULL
ug/ml	NULL
)	NULL
during	NULL
48	NULL
h.	NULL
After	NULL
the	NULL
culture	NULL
period	NULL
,	NULL
supernatants	NULL
were	NULL
analyzed	NULL
for	NULL
IL-6	NULL
in	NULL
an	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Monoclonal	NULL
antibody	NULL
and	NULL
polyclonal	NULL
sheep	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
Induces	NULL
IL-1B	NULL
and	NULL
IL-6	NULL
Expression	NULL
CH	NULL
;	NULL
OH	NULL
CH	NULL
o	NULL
0	NULL
0	NULL
OH	NULL
O	NULL
fo	NULL
Nag	NULL
Nam	NULL
ho	NULL
H	NULL
NHAc	NULL
NHAc	NULL
o	NULL
CH	NULL
nc	NULL
,	NULL
MH	NULL
L-Ala	NULL
H	NULL
0	NULL
H	NULL
D-iso	NULL
Gin	NULL
coon	NULL
o	NULL
NH	NULL
ooc	NULL
m-Dap	NULL
HaN	NULL
H	NULL
o	NULL
D-Ala	NULL
HN	NULL
_	NULL
4	NULL
ox	NULL
CHz	NULL
OH	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Structure	NULL
of	NULL
Tetra	NULL
.	NULL

anti-human	NULL
IL-6	NULL
were	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
L.	NULL
Aarden	NULL
.	NULL

The	NULL
detection	NULL
limit	NULL
of	NULL
this	NULL
assay	NULL
is	NULL
5	NULL
pg/ml	NULL
.	NULL

Secreted	NULL
IL-1	NULL
protein	NULL
in	NULL
supernatants	NULL
was	NULL
quantified	NULL
using	NULL
a	NULL
human	NULL
IL-18	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
kit	NULL
(	NULL
Cistron	NULL
Biotechnology	NULL
,	NULL
Pine	NULL
Brook	NULL
,	NULL
NJ	NULL
)	NULL
as	NULL
recommended	NULL
by	NULL
the	NULL
manufacturer	NULL
.	NULL

The	NULL
detection	NULL
limit	NULL
of	NULL
this	NULL
assay	NULL
is	NULL
2	NULL
pg/ml	NULL
.	NULL

The	NULL
Student	NULL
's	NULL
t	NULL
test	NULL
for	NULL
paired	NULL
samples	NULL
was	NULL
used	NULL
to	NULL
determine	NULL
the	NULL
significance	NULL
of	NULL
the	NULL
secretion	NULL
data	NULL
.	NULL

Run-on	NULL
Transcription	NULL
Assay-The	NULL
run-on	NULL
analysis	NULL
was	NULL
performed	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
32	NULL
)	NULL
using	NULL
pooled	NULL
nuclei	NULL
of	NULL
3	NULL
donors	NULL
.	NULL

Cells	NULL
were	NULL
treated	NULL
with	NULL
medium	NULL
(	NULL
control	NULL
)	NULL
or	NULL
1.25	NULL
ug/ml	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
for	NULL
1	NULL
or	NULL
2	NULL
h.	NULL
Five	NULL
ug	NULL
of	NULL
the	NULL
following	NULL
DNAs	NULL
were	NULL
immobilized	NULL
on	NULL
Hybond	NULL
N+	NULL
membranes	NULL
(	NULL
33	NULL
)	NULL
:	NULL
1	NULL
)	NULL
EcoRI	NULL
linearized	NULL
pGEM	NULL
(	NULL
negative	NULL
control	NULL
)	NULL
;	NULL
2	NULL
)	NULL
EcoRI	NULL
linearized	NULL
plasmid	NULL
containing	NULL
a	NULL
0.3-kb	NULL
fragment	NULL
of	NULL
the	NULL
human	NULL
IL-6	NULL
cDNA	NULL
;	NULL
3	NULL
)	NULL
EcoRI	NULL
linearized	NULL
plasmid	NULL
containing	NULL
a	NULL
0.57-kb	NULL
fragment	NULL
of	NULL
the	NULL
human	NULL
IL-18	NULL
cDNA	NULL
;	NULL
4	NULL
)	NULL
EcoRI	NULL
linearized	NULL
plasmid	NULL
containing	NULL
a	NULL
7.8-kb	NULL
insert	NULL
of	NULL
the	NULL
human	NULL
28	NULL
S	NULL
DNA	NULL
fragment	NULL
.	NULL

Hybridization	NULL
of	NULL
labeled	NULL
RNAs	NULL
to	NULL
these	NULL
membranes	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Nuclear	NULL
Extract	NULL
Preparation-After	NULL
stimulation	NULL
for	NULL
various	NULL
time	NULL
periods	NULL
nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
according	NULL
to	NULL
a	NULL
miniscale	NULL
procedure	NULL
as	NULL
described	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
divided	NULL
in	NULL
small	NULL
aliquots	NULL
,	NULL
frozen	NULL
in	NULL
liquid	NULL
NJ	NULL
,	NULL
and	NULL
stored	NULL
at	NULL
~80	NULL
°C	NULL
.	NULL

Electrophoretic	NULL
Mobility	NULL
Shift	NULL
Assay-The	NULL
probes	NULL
used	NULL
in	NULL
the	NULL
gel	NULL
retardation	NULL
assays	NULL
were	NULL
constructed	NULL
by	NULL
hybridization	NULL
of	NULL
two	NULL
20-mers	NULL
resulting	NULL
in	NULL
a	NULL
NF-	NULL
«	NULL
B-like	NULL
recognition	NULL
site	NULL
(	NULL
underlined	NULL
)	NULL
that	NULL
is	NULL
present	NULL
in	NULL
both	NULL
the	NULL
IL-18	NULL
and	NULL
IL-6	NULL
promoter	NULL
regions	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
:	NULL
5'-AGCTGCGGG-GATTTTCCCTG-3	NULL
'	NULL
and	NULL
3'-CGCCCCTAAAAGGGACCTAG-5	NULL
'	NULL
or	NULL
by	NULL
19-mers	NULL
spanning	NULL
the	NULL
AP-1	NULL
consensus	NULL
target	NULL
sequence	NULL
(	NULL
37	NULL
,	NULL
38	NULL
)	NULL
.	NULL

Probes	NULL
were	NULL
labeled	NULL
,	NULL
and	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
using	NULL
9	NULL
ng	NULL
of	NULL
nuclear	NULL
extract/reaction	NULL
(	NULL
38	NULL
)	NULL
.	NULL

The	NULL
same	NULL
batches	NULL
of	NULL
proteins	NULL
and	NULL
labeled	NULL
oligonucleotides	NULL
were	NULL
used	NULL
in	NULL
the	NULL
reactions	NULL
presented	NULL
in	NULL
the	NULL
figures	NULL
.	NULL

Competition	NULL
experiments	NULL
were	NULL
performed	NULL
by	NULL
adding	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabeled	NULL
self-	NULL
or	NULL
nonself-probes	NULL
before	NULL
preincubation	NULL
on	NULL
ice	NULL
.	NULL

RESULTS	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
Induces	NULL
IL-1B	NULL
and	NULL
IL-6	NULL
mRNA	NULL
Expression	NULL
in	NULL
Human	NULL
Monocytes-To	NULL
determine	NULL
whether	NULL
Tetra	NULL
induces	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
in	NULL
human	NULL
monocytes	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
either	NULL
with	NULL
culture	NULL
medium	NULL
(	NULL
control	NULL
)	NULL
or	NULL
with	NULL
medium	NULL
plus	NULL
0.5	NULL
ug/ml	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
for	NULL
2	NULL
,	NULL
4	NULL
,	NULL
8	NULL
,	NULL
and	NULL
15	NULL
h.	NULL
Total	NULL
RNA	NULL
was	NULL
isolated	NULL
and	NULL
subjected	NULL
to	NULL
Northern	NULL
analysis	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
both	NULL
IL-18B	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
is	NULL
induced	NULL
by	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
.	NULL

A	NULL
first	NULL
peak	NULL
in	NULL
IL-18B	NULL
and	NULL
IL-6	NULL
expression	NULL
was	NULL
noticed	NULL
after	NULL
2	NULL
h	NULL
of	NULL
stimulation	NULL
.	NULL

Interestingly	NULL
,	NULL
a	NULL
second	NULL
peak	NULL
in	NULL
mRNA	NULL
expression	NULL
was	NULL
found	NULL
after	NULL
a	NULL
15-h	NULL
stimulation	NULL
period	NULL
.	NULL

This	NULL
second	NULL
peak	NULL
could	NULL
be	NULL
inhibited	NULL
by	NULL
anti-IL-18	NULL
plus	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
Induces	NULL
IL-1B	NULL
and	NULL
IL-6	NULL
Expression	NULL
A.	NULL
time	NULL
(	NULL
h	NULL
)	NULL
-	NULL
0	NULL
2	NULL
4	NULL
8	NULL
15	NULL
IL-6	NULL
%	NULL
.	NULL

‘	NULL
IL-1	NULL
-	NULL
#	NULL
‘	NULL
B.	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Kinetics	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-18	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
in	NULL
human	NULL
monocytes	NULL
.	NULL

A	NULL
,	NULL
Northern	NULL
analysis	NULL
of	NULL
total	NULL
monocyte	NULL
RNA	NULL
extracted	NULL
at	NULL
different	NULL
time	NULL
points	NULL
(	NULL
indicated	NULL
)	NULL
after	NULL
activation	NULL
with	NULL
0.5	NULL
ug/ml	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
.	NULL

B	NULL
,	NULL
ethidium	NULL
bromide-stained	NULL
RNA	NULL
gel	NULL
to	NULL
show	NULL
equal	NULL
amounts	NULL
of	NULL
RNA	NULL
in	NULL
each	NULL
lane	NULL
.	NULL

anti-IL-1	NULL
«	NULL
monoclonal	NULL
antibodies	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
indicating	NULL
that	NULL
it	NULL
was	NULL
an	NULL
indirect	NULL
effect	NULL
mediated	NULL
through	NULL
the	NULL
release	NULL
of	NULL
these	NULL
cytokines	NULL
.	NULL

As	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
the	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
expression	NULL
of	NULL
IL-1	NULL
and	NULL
IL-6	NULL
mRNA	NULL
was	NULL
dose-dependent	NULL
.	NULL

Maximal	NULL
induction	NULL
of	NULL
IL-1B	NULL
and	NULL
IL-6	NULL
mRNA	NULL
was	NULL
observed	NULL
at	NULL
a	NULL
dose	NULL
of	NULL
1.25	NULL
ug/ml	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
.	NULL

To	NULL
achieve	NULL
maximal	NULL
expression	NULL
of	NULL
both	NULL
genes	NULL
in	NULL
further	NULL
experiments	NULL
,	NULL
monocytes	NULL
were	NULL
activated	NULL
with	NULL
1.25	NULL
ug/ml	NULL
Tetra	NULL
.	NULL

G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
Induces	NULL
Secretion	NULL
of	NULL
IL-1B	NULL
and	NULL
IL-6	NULL
Protein-To	NULL
study	NULL
the	NULL
ability	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
to	NULL
induce	NULL
IL-18	NULL
and	NULL
IL-6	NULL
protein	NULL
expression	NULL
we	NULL
determined	NULL
IL-1	NULL
$	NULL
and	NULL
IL-6	NULL
secretion	NULL
levels	NULL
in	NULL
supernatants	NULL
of	NULL
human	NULL
monocytes	NULL
that	NULL
were	NULL
cultured	NULL
for	NULL
48	NULL
h	NULL
in	NULL
medium	NULL
(	NULL
control	NULL
)	NULL
or	NULL
medium	NULL
plus	NULL
Tetra	NULL
.	NULL

Very	NULL
low	NULL
levels	NULL
of	NULL
IL-18	NULL
(	NULL
83.4	NULL
pg/ml	NULL
+	NULL
46.8	NULL
;	NULL
mean	NULL
+	NULL
S.D	NULL
.	NULL

,	NULL
n	NULL
=	NULL
5	NULL
)	NULL
and	NULL
IL-6	NULL
(	NULL
71.0	NULL
pg/ml	NULL
+	NULL
35.8	NULL
;	NULL
mean	NULL
+	NULL
S.D	NULL
.	NULL

,	NULL
n	NULL
=	NULL
5	NULL
)	NULL
were	NULL
measured	NULL
in	NULL
control	NULL
cells	NULL
.	NULL

Protein	NULL
levels	NULL
were	NULL
significantly	NULL
(	NULL
p	NULL
<	NULL
0.005	NULL
)	NULL
increased	NULL
to	NULL
773.6	NULL
pg/ml	NULL
+	NULL
271.6	NULL
(	NULL
mean	NULL
+	NULL
S.D	NULL
.	NULL

,	NULL
n	NULL
=	NULL
5	NULL
)	NULL
for	NULL
IL-1B	NULL
and	NULL
to	NULL
847.0	NULL
pg/ml	NULL
+	NULL
310.5	NULL
(	NULL
mean	NULL
+	NULL
S.D	NULL
.	NULL

,	NULL
n	NULL
=	NULL
5	NULL
)	NULL
for	NULL
IL-6	NULL
.	NULL

This	NULL
indicates	NULL
that	NULL
Tetra	NULL
also	NULL
induces	NULL
IL-18	NULL
and	NULL
IL-6	NULL
protein	NULL
expression	NULL
in	NULL
human	NULL
monocytes	NULL
,	NULL
and	NULL
it	NULL
underscores	NULL
the	NULL
relevance	NULL
of	NULL
the	NULL
mRNA	NULL
data	NULL
.	NULL

G	NULL
(	NULL
Ankh	NULL
)	NULL
MTetra	NULL
Induces	NULL
the	NULL
Transcription	NULL
Rates	NULL
of	NULL
the	NULL
IL-1B	NULL
and	NULL
IL-6	NULL
Genes-Run-on	NULL
transcription	NULL
assays	NULL
were	NULL
performed	NULL
to	NULL
determine	NULL
whether	NULL
the	NULL
effects	NULL
of	NULL
Tetra	NULL
on	NULL
the	NULL
IL-18B	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
are	NULL
mediated	NULL
through	NULL
transcriptional	NULL
mechanisms	NULL
.	NULL

Nuclear	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
cells	NULL
that	NULL
were	NULL
treated	NULL
with	NULL
medium	NULL
(	NULL
control	NULL
)	NULL
or	NULL
with	NULL
medium	NULL
plus	NULL
Tetra	NULL
for	NULL
1	NULL
and	NULL
2	NULL
h.	NULL
Nuclear	NULL
RNA	NULL
was	NULL
hybridized	NULL
to	NULL
pGEM	NULL
(	NULL
negative	NULL
control	NULL
)	NULL
,	NULL
IL-1	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
28	NULL
S	NULL
DNAs	NULL
.	NULL

Control	NULL
cells	NULL
demonstrated	NULL
a	NULL
low	NULL
constitutive	NULL
transcription	NULL
rate	NULL
of	NULL
the	NULL
IL-1	NULL
$	NULL
and	NULL
IL-6	NULL
genes	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

The	NULL
rate	NULL
of	NULL
IL-1	NULL
$	NULL
B	NULL
transcription	NULL
was	NULL
rapidly	NULL
and	NULL
strongly	NULL
enhanced	NULL
by	NULL
Tetra	NULL
and	NULL
was	NULL
maximal	NULL
after	NULL
1	NULL
h	NULL
of	NULL
treatment	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

Transcriptional	NULL
activity	NULL
of	NULL
the	NULL
IL-6	NULL
gene	NULL
was	NULL
less	NULL
pronounced	NULL
and	NULL
reached	NULL
maximal	NULL
levels	NULL
after	NULL
2	NULL
h	NULL
of	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

G	NULL
(	NULL
Ankh	NULL
)	NULL
MTetra	NULL
Induces	NULL
NF-kB	NULL
and	NULL
AP-1	NULL
Transcription	NULL
Factor	NULL
Expression-Studies	NULL
on	NULL
the	NULL
promoter	NULL
regions	NULL
of	NULL
the	NULL
IL-18B	NULL
and	NULL
IL-6	NULL
genes	NULL
suggested	NULL
possible	NULL
roles	NULL
for	NULL
several	NULL
transcription	NULL
factors	NULL
in	NULL
the	NULL
control	NULL
of	NULL
the	NULL
transcriptional	NULL
rates	NULL
of	NULL
these	NULL
4203	NULL
A	NULL
.	NULL

3	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
b	NULL
wo	NULL
conc	NULL
.	NULL

(	NULL
ug/ml	NULL
)	NULL
§	NULL
8	NULL
IS	NULL
3	NULL
if	NULL
?	NULL

Me	NULL
:	NULL
IL-6	NULL
IL-1	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Dose-response	NULL
curve	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-1	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
.	NULL

A	NULL
,	NULL
Northern	NULL
analysis	NULL
of	NULL
total	NULL
RNA	NULL
extracted	NULL
after	NULL
2	NULL
h	NULL
of	NULL
stimulation	NULL
with	NULL
different	NULL
concentrations	NULL
(	NULL
conc	NULL
.	NULL
)	NULL

(	NULL
indicated	NULL
)	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
.	NULL

B	NULL
,	NULL
ethidium	NULL
bromide-stained	NULL
RNA	NULL
gel	NULL
to	NULL
show	NULL
equal	NULL
amounts	NULL
of	NULL
RNA	NULL
in	NULL
each	NULL
lane	NULL
.	NULL

A	NULL
.	NULL

B.	NULL
Tetra	NULL
(	NULL
60	NULL
)	NULL
Tetra	NULL
(	NULL
120	NULL
)	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
(	NULL
60	NULL
)	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
(	NULL
120	NULL
)	NULL
C	NULL
C	NULL
3	NULL
3	NULL
6	NULL
9	NULL
o	NULL
``	NULL
pGEM	NULL
pGEM	NULL
(	NULL
IL-1	NULL
©	NULL
_	NULL
a	NULL
IL-1	NULL
as	NULL
D.	NULL
IL-6	NULL
IL-6	NULL
N	NULL
288	NULL
28S8	NULL
U	NULL
#	NULL
#	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Effect	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
on	NULL
the	NULL
transcription	NULL
rate	NULL
of	NULL
the	NULL
IL-1¢	NULL
and	NULL
IL-6	NULL
genes	NULL
.	NULL

Nuclear	NULL
run-on	NULL
experiment	NULL
.	NULL

Nuclei	NULL
were	NULL
prepared	NULL
from	NULL
human	NULL
monocytes	NULL
that	NULL
were	NULL
treated	NULL
with	NULL
medium	NULL
(	NULL
control	NULL
)	NULL
or	NULL
with	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
for	NULL
1	NULL
and	NULL
2	NULL
h.	NULL
Transcription	NULL
in	NULL
the	NULL
isolated	NULL
nuclei	NULL
was	NULL
analyzed	NULL
by	NULL
hybridization	NULL
of	NULL
the	NULL
**P	NULL
transcripts	NULL
to	NULL
5	NULL
ug	NULL
of	NULL
linearized	NULL
plasmids	NULL
containing	NULL
no	NULL
insert	NULL
(	NULL
pGEM	NULL
)	NULL
,	NULL
IL-1B	NULL
,	NULL
IL-6	NULL
,	NULL
and	NULL
28	NULL
S	NULL
cDNA	NULL
inserts	NULL
immobilized	NULL
on	NULL
nylon	NULL
membranes	NULL
.	NULL

Depicted	NULL
are	NULL
an	NULL
autoradiogram	NULL
after	NULL
8	NULL
h	NULL
of	NULL
exposure	NULL
(	NULL
A	NULL
)	NULL
demonstrating	NULL
the	NULL
increase	NULL
in	NULL
IL-18B	NULL
transcription	NULL
rate	NULL
and	NULL
a	NULL
100-h	NULL
(	NULL
B	NULL
)	NULL
exposure	NULL
of	NULL
the	NULL
same	NULL
autoradiogram	NULL
demonstrating	NULL
the	NULL
increase	NULL
in	NULL
IL-6	NULL
transcription	NULL
rate	NULL
.	NULL

genes	NULL
(	NULL
39	NULL
,	NULL
40	NULL
)	NULL
.	NULL

Relevant	NULL
transcription	NULL
factors	NULL
were	NULL
shown	NULL
to	NULL
be	NULL
activator	NULL
protein-1	NULL
(	NULL
AP-1	NULL
)	NULL
,	NULL
cyclic	NULL
AMP	NULL
responsive	NULL
element	NULL
,	NULL
nuclear	NULL
factor	NULL
IL-6	NULL
(	NULL
NF-IL6	NULL
)	NULL
,	NULL
and	NULL
nuclear	NULL
factor-	NULL
«	NULL
B	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
.	NULL

To	NULL
study	NULL
the	NULL
expression	NULL
of	NULL
these	NULL
transcription	NULL
factors	NULL
after	NULL
Tetra	NULL
treatment	NULL
,	NULL
the	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
was	NULL
performed	NULL
.	NULL

Because	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
cytokine	NULL
mRNA	NULL
expression	NULL
reaches	NULL
maximal	NULL
levels	NULL
after	NULL
2	NULL
h	NULL
of	NULL
treatment	NULL
,	NULL
transcription	NULL
factor	NULL
expression	NULL
was	NULL
studied	NULL
after	NULL
short	NULL
incubation	NULL
periods	NULL
with	NULL
Tetra	NULL
.	NULL

Nuclear	NULL
extracts	NULL
,	NULL
prepared	NULL
from	NULL
monocytes	NULL
that	NULL
were	NULL
exposed	NULL
to	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
for	NULL
4204	NULL
Tetra	NULL
Mer	NULL
b3	NULL
-o	NULL
&	NULL
2	NULL
2	NULL
§	NULL
8	NULL
&	NULL
z	NULL
0	NULL
Lelie	NULL
«	NULL
-	NULL
]	NULL
8	NULL
NON	NULL
_	NULL
~	NULL
s	NULL
=-	NULL
®	NULL
-	NULL
--	NULL
AP-1	NULL
NF-	NULL
«	NULL
B	NULL
FREE	NULL
PROBE	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Effect	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
AP-1	NULL
and	NULL
NF-xB	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
transcription	NULL
factor	NULL
expression	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
control	NULL
monocytes	NULL
and	NULL
from	NULL
monocytes	NULL
that	NULL
were	NULL
treated	NULL
with	NULL
1.25	NULL
ug/ml	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
for	NULL
15	NULL
,	NULL
30	NULL
,	NULL
60	NULL
,	NULL
and	NULL
120	NULL
min	NULL
.	NULL

Extracts	NULL
were	NULL
incubated	NULL
with	NULL
**P-labeled	NULL
oligonucleotides	NULL
containing	NULL
an	NULL
AP-1	NULL
and	NULL
NF-kB	NULL
target	NULL
sequence	NULL
.	NULL

After	NULL
incubation	NULL
,	NULL
the	NULL
mixtures	NULL
were	NULL
separated	NULL
by	NULL
electrophoresis	NULL
.	NULL

Competition	NULL
experiments	NULL
were	NULL
performed	NULL
with	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
nonlabeled	NULL
self-	NULL
and	NULL
nonself-oligonucleo-tides	NULL
using	NULL
the	NULL
extracts	NULL
that	NULL
were	NULL
isolated	NULL
after	NULL
60	NULL
min	NULL
.	NULL

An	NULL
excess	NULL
of	NULL
free	NULL
probe	NULL
was	NULL
used	NULL
in	NULL
every	NULL
experiment	NULL
but	NULL
is	NULL
only	NULL
shown	NULL
for	NULL
NF-kB	NULL
.	NULL

Duplicate	NULL
experiments	NULL
with	NULL
other	NULL
batches	NULL
showed	NULL
similar	NULL
results	NULL
.	NULL

15	NULL
,	NULL
30	NULL
,	NULL
60	NULL
,	NULL
and	NULL
120	NULL
min	NULL
and	NULL
control	NULL
cells	NULL
,	NULL
were	NULL
incubated	NULL
with	NULL
synthetic	NULL
double-stranded	NULL
oligonucleotide	NULL
spanning	NULL
the	NULL
AP-1	NULL
,	NULL
cyclic	NULL
AMP	NULL
responsive	NULL
element	NULL
,	NULL
NF-IL6	NULL
,	NULL
and	NULL
NF-kB	NULL
binding	NULL
sites	NULL
.	NULL

A	NULL
representative	NULL
experiment	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Control	NULL
cells	NULL
demonstrated	NULL
a	NULL
low	NULL
constitutive	NULL
level	NULL
of	NULL
AP-1	NULL
and	NULL
NF-kB	NULL
.	NULL

Upon	NULL
treatment	NULL
with	NULL
Tetra	NULL
,	NULL
both	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
expressions	NULL
are	NULL
enhanced	NULL
and	NULL
reach	NULL
maximum	NULL
levels	NULL
after	NULL
120	NULL
min	NULL
of	NULL
treatment	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
NF-IL6	NULL
and	NULL
cyclic	NULL
AMP	NULL
responsive	NULL
element	NULL
levels	NULL
were	NULL
not	NULL
affected	NULL
by	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Protein-DNA	NULL
complexes	NULL
were	NULL
specifically	NULL
competed	NULL
by	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
the	NULL
nonlabeled	NULL
self-oligonucleo-tide	NULL
but	NULL
not	NULL
by	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
a	NULL
nonself-oligonucleo-tide	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
showing	NULL
that	NULL
protein-DNA	NULL
complexes	NULL
were	NULL
specific	NULL
.	NULL

Signal	NULL
Transduction	NULL
Pathways	NULL
and	NULL
Protein	NULL
Synthesis	NULL
Dependence	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-1B	NULL
and	NULL
IL-6	NULL
mRNA	NULL
Expres-sion-To	NULL
assess	NULL
the	NULL
involvement	NULL
of	NULL
signal	NULL
transduction	NULL
pathways	NULL
during	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-1B	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
,	NULL
we	NULL
pretreated	NULL
monocytes	NULL
with	NULL
the	NULL
protein	NULL
kinase	NULL
A	NULL
inhibitor	NULL
H8	NULL
,	NULL
with	NULL
H7	NULL
,	NULL
as	NULL
well	NULL
as	NULL
with	NULL
the	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
genistein	NULL
,	NULL
before	NULL
stimulation	NULL
with	NULL
Tetra	NULL
.	NULL

H8	NULL
and	NULL
genistein	NULL
showed	NULL
no	NULL
effect	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
H7	NULL
blocked	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-1	NULL
$	NULL
8	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
suggesting	NULL
the	NULL
involvement	NULL
of	NULL
the	NULL
protein	NULL
kinase	NULL
C	NULL
pathway	NULL
during	NULL
this	NULL
process	NULL
.	NULL

To	NULL
study	NULL
the	NULL
protein	NULL
synthesis	NULL
dependence	NULL
,	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
Induces	NULL
IL-1B	NULL
and	NULL
IL-6	NULL
Expression	NULL
A.	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
.S	NULL
s	NULL
2	NULL
§	NULL
.ms	NULL
P	NULL
s	NULL
|	NULL
x	NULL
=	NULL
5	NULL
IL-6	NULL
U	NULL
#	NULL
#	NULL
IL-1	NULL
U	NULL
-	NULL
¥VW	NULL
B.	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

Effect	NULL
of	NULL
specific	NULL
inhibitors	NULL
on	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-	NULL
induced	NULL
IL-1	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
.	NULL

A	NULL
,	NULL
Northern	NULL
analysis	NULL
of	NULL
total	NULL
RNA	NULL
extracted	NULL
from	NULL
monocytes	NULL
that	NULL
were	NULL
treated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
the	NULL
indicated	NULL
inhibitors	NULL
and	NULL
subsequently	NULL
with	NULL
1.25	NULL
ug/ml	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
for	NULL
2	NULL
h.	NULL
B	NULL
,	NULL
ethidium	NULL
bromide-stained	NULL
RNA	NULL
gel	NULL
to	NULL
show	NULL
equal	NULL
amounts	NULL
of	NULL
RNA	NULL
in	NULL
each	NULL
lane	NULL
.	NULL

A.	NULL
E	NULL
3	NULL
p	NULL
z	NULL
2	NULL
f	NULL
€	NULL
&	NULL
5	NULL
&	NULL
a2	NULL
.	NULL

%	NULL
..	NULL
L	NULL
T	NULL
E	NULL
x	NULL
x	NULL
2	NULL
E	NULL
E	NULL
%	NULL
§	NULL
05	NULL
5	NULL
5	NULL
IL-6	NULL
bf	NULL
ma	NULL
..	NULL
t	NULL
us	NULL
B.	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

Effect	NULL
of	NULL
the	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
cycloheximide	NULL
on	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-18	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
.	NULL

A	NULL
,	NULL
Northern	NULL
analysis	NULL
of	NULL
monocytes	NULL
that	NULL
were	NULL
treated	NULL
with	NULL
CHX	NULL
for	NULL
30	NULL
min	NULL
,	NULL
CHX	NULL
for	NULL
30	NULL
min	NULL
plus	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
for	NULL
2	NULL
h	NULL
or	NULL
with	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
for	NULL
2	NULL
h.	NULL
B	NULL
,	NULL
ethidium	NULL
bromide-stained	NULL
RNA	NULL
gel	NULL
to	NULL
show	NULL
equal	NULL
amounts	NULL
of	NULL
RNA	NULL
in	NULL
each	NULL
lane	NULL
.	NULL

monocytes	NULL
were	NULL
incubated	NULL
with	NULL
CHX	NULL
,	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
M	NULL
Tetra	NULL
,	NULL
and	NULL
with	NULL
CHX	NULL
plus	NULL
Tetra	NULL
.	NULL

CHX	NULL
blocked	NULL
the	NULL
ability	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
to	NULL
induce	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
,	NULL
indicating	NULL
that	NULL
this	NULL
induction	NULL
depends	NULL
on	NULL
the	NULL
synthesis	NULL
of	NULL
new	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
monocytes	NULL
exposed	NULL
to	NULL
CHX	NULL
only	NULL
,	NULL
superinduced	NULL
levels	NULL
of	NULL
IL-16	NULL
mRNA	NULL
,	NULL
which	NULL
could	NULL
be	NULL
further	NULL
augmented	NULL
by	NULL
exposure	NULL
to	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
,	NULL
indicating	NULL
that	NULL
protein	NULL
synthesis	NULL
is	NULL
not	NULL
required	NULL
for	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-18	NULL
mRNA	NULL
expression	NULL
.	NULL

Magnitude	NULL
of	NULL
IL-6	NULL
and	NULL
IL-1B	NULL
mRNA	NULL
Expression	NULL
Induced	NULL
by	NULL
G	NULL
(	NULL
Ank	NULL
)	NULL
MTetra	NULL
,	NULL
LPS	NULL
,	NULL
and	NULL
MDP-To	NULL
study	NULL
the	NULL
relative	NULL
amount	NULL
of	NULL
IL-6	NULL
and	NULL
IL-16B	NULL
mRNA	NULL
that	NULL
is	NULL
induced	NULL
by	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
,	NULL
mRNA	NULL
levels	NULL
were	NULL
compared	NULL
with	NULL
those	NULL
induced	NULL
by	NULL
LPS	NULL
and	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
Induces	NULL
IL-1B	NULL
and	NULL
IL-6	NULL
Expression	NULL
MDP	NULL
.	NULL

Maximal	NULL
IL-6	NULL
and	NULL
IL-1B	NULL
mRNA	NULL
was	NULL
expressed	NULL
at	NULL
0.5	NULL
ug/ml	NULL
LPS	NULL
and	NULL
5	NULL
ug/ml	NULL
MDP	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
monocytes	NULL
were	NULL
treated	NULL
with	NULL
1.25	NULL
ug/ml	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
,	NULL
0.5	NULL
ug/ml	NULL
LPS	NULL
,	NULL
and	NULL
5	NULL
ug/ml	NULL
MDP	NULL
.	NULL

Total	NULL
RNA	NULL
was	NULL
extracted	NULL
after	NULL
2	NULL
h	NULL
of	NULL
treatment	NULL
,	NULL
and	NULL
RNA	NULL
was	NULL
subjected	NULL
to	NULL
Northern	NULL
analysis	NULL
.	NULL

As	NULL
demonstrated	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
the	NULL
maximum	NULL
response	NULL
to	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
M-Tetra-induction	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
LPS	NULL
but	NULL
was	NULL
significantly	NULL
higher	NULL
than	NULL
the	NULL
response	NULL
to	NULL
MDP	NULL
.	NULL

Relative	NULL
mRNA	NULL
levels	NULL
were	NULL
calculated	NULL
by	NULL
densitometric	NULL
scanning	NULL
and	NULL
normalization	NULL
of	NULL
the	NULL
signals	NULL
to	NULL
the	NULL
respective	NULL
28	NULL
S	NULL
signals	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
.	NULL

Maximal	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-1	NULL
$	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
could	NULL
be	NULL
enhanced	NULL
by	NULL
co-stimulation	NULL
with	NULL
LPS	NULL
or	NULL
MDP	NULL
(	NULL
Figs	NULL
.	NULL

8	NULL
and	NULL
9	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
different	NULL
receptors	NULL
and/or	NULL
transduction	NULL
pathways	NULL
are	NULL
involved	NULL
.	NULL

A.	NULL
hd	NULL
$	NULL
5	NULL
t	NULL
.S	NULL
EE—	NULL
2	NULL
4	NULL
E	NULL
2	NULL
E	NULL
&	NULL
$	NULL
<	NULL
a	NULL
1	NULL
4	NULL
5	NULL
5	NULL
s	NULL
5	NULL
Z	NULL
a	NULL
A	NULL
.	NULL

8	NULL
<	NULL
Aa	NULL
z	NULL
A	NULL
z	NULL
Ss	NULL
o	NULL
%	NULL
i	NULL
&	NULL
3	NULL
o	NULL
W	NULL
WWW	NULL
tes	NULL
t	NULL
as	NULL
un	NULL
thas	NULL
B.	NULL
Fic	NULL
.	NULL

8	NULL
.	NULL

Comparison	NULL
of	NULL
magnitudes	NULL
of	NULL
IL-6	NULL
and	NULL
IL-1	NULL
mRNA	NULL
expression	NULL
.	NULL

A	NULL
,	NULL
Northern	NULL
analysis	NULL
of	NULL
monocytes	NULL
that	NULL
were	NULL
treated	NULL
for	NULL
2	NULL
h	NULL
with	NULL
1.25	NULL
ug/ml	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
,	NULL
5	NULL
ug/ml	NULL
MDP	NULL
,	NULL
0.5	NULL
ug/ml	NULL
LPS	NULL
,	NULL
or	NULL
combinations	NULL
of	NULL
these	NULL
.	NULL

B	NULL
,	NULL
ethidium	NULL
bromide-stained	NULL
RNA	NULL
gel	NULL
to	NULL
show	NULL
equal	NULL
amounts	NULL
of	NULL
RNA	NULL
in	NULL
each	NULL
lane	NULL
.	NULL

250	NULL
200	NULL
&	NULL
.0	NULL
$	NULL
§	NULL
.	NULL

Fic	NULL
.	NULL

9	NULL
.	NULL

Schematic	NULL
representation	NULL
of	NULL
<	NULL
IL-6	NULL
and	NULL
IL-1B	NULL
mRNA	NULL
levels	NULL
in	NULL
€	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-	NULL
,	NULL
MDP-	NULL
,	NULL
and	NULL
LPS-	NULL
E	NULL
treated	NULL
monocytes	NULL
.	NULL

Quantification	NULL
of	NULL
$	NULL
100	NULL
4	NULL
mRNA	NULL
levels	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
was	NULL
per-	NULL
®	NULL
formed	NULL
by	NULL
densitometric	NULL
scanning	NULL
,	NULL
and	NULL
4	NULL
levels	NULL
were	NULL
normalized	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
a	NULL
28	NULL
S	NULL
signals	NULL
.	NULL

50	NULL
0	NULL
4205	NULL
DISCUSSION	NULL
In	NULL
the	NULL
present	NULL
study	NULL
we	NULL
investigated	NULL
whether	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
,	NULL
which	NULL
is	NULL
a	NULL
naturally	NULL
occurring	NULL
1,6-anhydro	NULL
breakdown	NULL
product	NULL
of	NULL
bacterial	NULL
peptidoglycan	NULL
(	NULL
16	NULL
)	NULL
,	NULL
can	NULL
modulate	NULL
the	NULL
expression	NULL
of	NULL
inflammatory	NULL
cytokines	NULL
in	NULL
human	NULL
monocytes	NULL
.	NULL

The	NULL
results	NULL
demonstrate	NULL
that	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
induces	NULL
IL-18	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
.	NULL

This	NULL
expression	NULL
is	NULL
mediated	NULL
through	NULL
an	NULL
H7-inhibitable	NULL
pathway	NULL
that	NULL
might	NULL
include	NULL
a	NULL
protein	NULL
kinase	NULL
C-dependent	NULL
pathway	NULL
,	NULL
which	NULL
was	NULL
previously	NULL
described	NULL
to	NULL
be	NULL
the	NULL
most	NULL
important	NULL
transduction	NULL
pathway	NULL
mediating	NULL
LPS	NULL
responses	NULL
in	NULL
human	NULL
monocytes	NULL
(	NULL
41	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
Tetra	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
is	NULL
highly	NULL
defined	NULL
,	NULL
it	NULL
contains	NULL
approximately	NULL
10	NULL
%	NULL
of	NULL
other	NULL
1,6-anhydro-muramyl	NULL
peptides	NULL
,	NULL
which	NULL
may	NULL
also	NULL
be	NULL
biologically	NULL
active	NULL
(	NULL
16	NULL
)	NULL
.	NULL

G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-18B	NULL
and	NULL
IL-6	NULL
expression	NULL
was	NULL
accompanied	NULL
by	NULL
an	NULL
increase	NULL
in	NULL
the	NULL
transcription	NULL
rates	NULL
of	NULL
the	NULL
respective	NULL
genes	NULL
.	NULL

It	NULL
can	NULL
not	NULL
be	NULL
excluded	NULL
that	NULL
post-transcriptional	NULL
mechanisms	NULL
,	NULL
like	NULL
stabilization	NULL
of	NULL
cytokine	NULL
transcripts	NULL
,	NULL
also	NULL
account	NULL
for	NULL
the	NULL
strong	NULL
induction	NULL
of	NULL
IL-1	NULL
and	NULL
IL-6	NULL
mRNA	NULL
by	NULL
Tetra	NULL
.	NULL

For	NULL
example	NULL
,	NULL
for	NULL
IL-18	NULL
mRNA	NULL
expression	NULL
it	NULL
was	NULL
shown	NULL
that	NULL
the	NULL
half-life	NULL
of	NULL
LPS-induced	NULL
IL-1B	NULL
mRNA	NULL
was	NULL
4	NULL
versus	NULL
2.5	NULL
h	NULL
for	NULL
adherence-induced	NULL
IL-18	NULL
mRNA	NULL
(	NULL
42	NULL
)	NULL
.	NULL

One	NULL
of	NULL
the	NULL
elements	NULL
that	NULL
is	NULL
likely	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
post-transcriptional	NULL
control	NULL
of	NULL
IL-18B	NULL
mRNA	NULL
expression	NULL
is	NULL
an	NULL
unidentified	NULL
labile	NULL
protein	NULL
.	NULL

This	NULL
is	NULL
supported	NULL
by	NULL
studies	NULL
demonstrating	NULL
an	NULL
increased	NULL
stability	NULL
of	NULL
IL-18B	NULL
mRNA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CHX	NULL
(	NULL
43	NULL
,	NULL
44	NULL
)	NULL
.	NULL

The	NULL
increase	NULL
in	NULL
IL-6	NULL
message	NULL
may	NULL
significantly	NULL
be	NULL
ascribed	NULL
to	NULL
stabilization	NULL
of	NULL
IL-6	NULL
transcripts	NULL
,	NULL
because	NULL
a	NULL
slight	NULL
increase	NULL
in	NULL
the	NULL
transcription	NULL
rate	NULL
was	NULL
observed	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
post-transcriptional	NULL
control	NULL
is	NULL
the	NULL
most	NULL
prominent	NULL
level	NULL
of	NULL
control	NULL
for	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
upon	NULL
stimulation	NULL
with	NULL
Tetra	NULL
as	NULL
was	NULL
demonstrated	NULL
earlier	NULL
for	NULL
LPS-	NULL
versus	NULL
IFN-y	NULL
plus	NULL
LPS-induced	NULL
IL-6	NULL
mRNA	NULL
(	NULL
45	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
Tetra	NULL
on	NULL
IL-18	NULL
mRNA	NULL
expression	NULL
represented	NULL
modification	NULL
of	NULL
preexisting	NULL
proteins	NULL
rather	NULL
than	NULL
new	NULL
synthesis	NULL
,	NULL
because	NULL
pretreatment	NULL
with	NULL
CHX	NULL
did	NULL
not	NULL
abolish	NULL
the	NULL
effect	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
is	NULL
dependent	NULL
on	NULL
protein	NULL
synthesis	NULL
.	NULL

For	NULL
IL-1	NULL
$	NULL
,	NULL
these	NULL
results	NULL
are	NULL
in	NULL
accordance	NULL
with	NULL
data	NULL
suggesting	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
the	NULL
most	NULL
dominant	NULL
factor	NULL
controlling	NULL
transcription	NULL
(	NULL
43	NULL
,	NULL
46	NULL
)	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
exists	NULL
in	NULL
an	NULL
inactive	NULL
cytoplasmic	NULL
form	NULL
that	NULL
dissociates	NULL
on	NULL
phospho-rylation	NULL
of	NULL
the	NULL
inhibitory	NULL
protein	NULL
termed	NULL
IxB	NULL
(	NULL
47	NULL
,	NULL
48	NULL
)	NULL
.	NULL

Phospho-	NULL
C	NULL
=ILs	NULL
=IL-18	NULL
£	NULL
£	NULL
£	NULL
®	NULL
@	NULL
®	NULL
i	NULL
-	NULL
A	NULL
[	NULL
ad	NULL
3	NULL
3	NULL
o	NULL
=¢€	NULL
~	NULL
om	NULL
al	NULL
mal	NULL
<	NULL
‘	NULL
Eo	NULL
E0	NULL
<	NULL
<	NULL
<	NULL
G	NULL
6	NULL
foJ	NULL
4206	NULL
rylation	NULL
of	NULL
IxB	NULL
and	NULL
the	NULL
subsequent	NULL
release	NULL
of	NULL
active	NULL
NF-	NULL
«	NULL
B	NULL
from	NULL
the	NULL
cytoplasm	NULL
can	NULL
occur	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
newly	NULL
synthesized	NULL
protein	NULL
.	NULL

Most	NULL
studies	NULL
reported	NULL
so	NULL
far	NULL
described	NULL
NF-	NULL
«	NULL
B	NULL
as	NULL
the	NULL
most	NULL
important	NULL
factor	NULL
controlling	NULL
IL-6	NULL
transcription	NULL
(	NULL
49-52	NULL
)	NULL
.	NULL

However	NULL
,	NULL
CHX	NULL
plus	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
induces	NULL
without	NULL
inducing	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
,	NULL
indicating	NULL
that	NULL
additional	NULL
factors	NULL
are	NULL
involved	NULL
.	NULL

Possibly	NULL
,	NULL
the	NULL
strong	NULL
increase	NULL
in	NULL
AP-1	NULL
expression	NULL
upon	NULL
G	NULL
{	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
treatment	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
IL-6	NULL
transcription	NULL
rate	NULL
.	NULL

Supporting	NULL
this	NULL
sug-gestion	NULL
,	NULL
it	NULL
was	NULL
described	NULL
that	NULL
AP-1	NULL
mediates	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
transcription	NULL
rate	NULL
of	NULL
the	NULL
IL-6	NULL
gene	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
upon	NULL
stimulation	NULL
with	NULL
pokeweed	NULL
mitogen	NULL
(	NULL
53	NULL
)	NULL
.	NULL

Further	NULL
experiments	NULL
are	NULL
needed	NULL
to	NULL
exactly	NULL
define	NULL
the	NULL
transcription	NULL
factors	NULL
that	NULL
control	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-186	NULL
and	NULL
IL-6	NULL
expression	NULL
and	NULL
to	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
that	NULL
other	NULL
factors	NULL
bind	NULL
to	NULL
the	NULL
oligos	NULL
we	NULL
used	NULL
.	NULL

Optimal	NULL
expression	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra-induced	NULL
IL-1	NULL
$	NULL
and	NULL
IL-6	NULL
mRNA	NULL
expression	NULL
could	NULL
be	NULL
further	NULL
enhanced	NULL
by	NULL
costimulation	NULL
with	NULL
optimal	NULL
doses	NULL
of	NULL
LPS	NULL
or	NULL
MDP	NULL
.	NULL

This	NULL
finding	NULL
suggests	NULL
that	NULL
different	NULL
receptors	NULL
and/or	NULL
additional	NULL
intracellular	NULL
transduction	NULL
pathways	NULL
are	NULL
involved	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
different	NULL
receptors	NULL
for	NULL
LPS	NULL
,	NULL
Tetra	NULL
,	NULL
and	NULL
MDP	NULL
is	NULL
underscored	NULL
by	NULL
the	NULL
findings	NULL
of	NULL
Dziarski	NULL
(	NULL
54	NULL
,	NULL
55	NULL
)	NULL
who	NULL
observed	NULL
that	NULL
neither	NULL
MDP	NULL
nor	NULL
Tetra	NULL
competed	NULL
for	NULL
LPS	NULL
binding	NULL
sites	NULL
on	NULL
murine	NULL
macrophages	NULL
.	NULL

Recently	NULL
,	NULL
it	NULL
was	NULL
suggested	NULL
that	NULL
MDP	NULL
and	NULL
LPS	NULL
responses	NULL
of	NULL
murine	NULL
monocytes	NULL
were	NULL
mediated	NULL
through	NULL
binding	NULL
to	NULL
different	NULL
receptors	NULL
(	NULL
56	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
in	NULL
the	NULL
development	NULL
of	NULL
sepsis	NULL
is	NULL
hypothetical	NULL
.	NULL

However	NULL
,	NULL
the	NULL
strong	NULL
and	NULL
relatively	NULL
quick	NULL
induction	NULL
of	NULL
two	NULL
inflammatory	NULL
cytokines	NULL
in	NULL
monocytes	NULL
after	NULL
exposure	NULL
to	NULL
Tetra	NULL
is	NULL
suggestive	NULL
.	NULL

Apart	NULL
from	NULL
a	NULL
possible	NULL
role	NULL
in	NULL
the	NULL
development	NULL
of	NULL
Gram-negative	NULL
sepsis	NULL
,	NULL
Tetra	NULL
might	NULL
be	NULL
a	NULL
factor	NULL
responsible	NULL
for	NULL
sepsis	NULL
caused	NULL
by	NULL
Gram-positive	NULL
bacteria	NULL
.	NULL

As	NULL
the	NULL
action	NULL
of	NULL
the	NULL
soluble	NULL
lytic	NULL
transglycosylases	NULL
are	NULL
thought	NULL
to	NULL
be	NULL
triggered	NULL
by	NULL
certain	NULL
antibiotics	NULL
that	NULL
are	NULL
directed	NULL
against	NULL
cell	NULL
wall	NULL
metabolism	NULL
(	NULL
57	NULL
)	NULL
,	NULL
application	NULL
of	NULL
these	NULL
antibiotics	NULL
may	NULL
stimulate	NULL
cytokine	NULL
expression	NULL
by	NULL
the	NULL
release	NULL
of	NULL
G	NULL
(	NULL
Anb	NULL
)	NULL
MTetra	NULL
.	NULL

To	NULL
test	NULL
these	NULL
hypotheses	NULL
,	NULL
it	NULL
would	NULL
be	NULL
useful	NULL
to	NULL
examine	NULL
a	NULL
monoclonal	NULL
raised	NULL
against	NULL
the	NULL
1,6-anhydro	NULL
bond	NULL
of	NULL
G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
,	NULL
for	NULL
its	NULL
ability	NULL
to	NULL
inhibit	NULL
cytokine	NULL
expression	NULL
in	NULL
human	NULL
monocytes	NULL
treated	NULL
with	NULL
extracts	NULL
of	NULL
Gram-negative	NULL
or	NULL
Gram-positive	NULL
bacteria	NULL
.	NULL

Acknowledgments-We	NULL
are	NULL
grateful	NULL
to	NULL
Dr.	NULL
S.	NULL
Gillis	NULL
for	NULL
the	NULL
IL-18B	NULL
cDNA	NULL
probe	NULL
and	NULL
polyclonal	NULL
anti-IL1a	NULL
«	NULL
and	NULL
IL-18	NULL
and	NULL
Dr.	NULL
L.	NULL
Aarden	NULL
for	NULL
gift	NULL
of	NULL
the	NULL
IL-6	NULL
cDNA	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
P.	NULL
Limburg	NULL
and	NULL
J.	NULL
Bijzet	NULL
for	NULL
performing	NULL
the	NULL
IL-6	NULL
and	NULL
M.	NULL
T.	NULL
Esselink	NULL
for	NULL
performing	NULL
the	NULL
IL-18	NULL
secretion	NULL
experiments	NULL
,	NULL
respectively	NULL
.	NULL

We	NULL
thank	NULL
A.	NULL
van	NULL
Leeuwen	NULL
and	NULL
Dr.	NULL
H.	NULL
Engel	NULL
for	NULL
isolating	NULL
Tetra	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
Drs	NULL
.	NULL

A.	NULL
R.	NULL
van	NULL
Buuren	NULL
,	NULL
M.	NULL
Lubben	NULL
,	NULL
M.	NULL
Ottens	NULL
,	NULL
and	NULL
A.	NULL
de	NULL
Vries	NULL
for	NULL
help	NULL
in	NULL
initiating	NULL
the	NULL
project	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Parrillo	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1990	NULL
)	NULL
Ann	NULL
.	NULL

Intern	NULL
.	NULL

Med	NULL
.	NULL

118	NULL
,	NULL
227-242	NULL
2	NULL
.	NULL

Munoz	NULL
,	NULL
C.	NULL
,	NULL
Carlet	NULL
,	NULL
J.	NULL
,	NULL
Fitting	NULL
,	NULL
C.	NULL
,	NULL
Misset	NULL
,	NULL
B.	NULL
,	NULL
Blériot	NULL
,	NULL
J.-P.	NULL
&	NULL
Cavaillon	NULL
,	NULL
J.-M.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

88	NULL
,	NULL
1747-1754	NULL
3	NULL
.	NULL

Parrillo	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

328	NULL
,	NULL
1471-1477	NULL
4	NULL
.	NULL

McCabe	NULL
,	NULL
W.	NULL
R.	NULL
&	NULL
Olans	NULL
,	NULL
R.	NULL
W.	NULL
(	NULL
1981	NULL
)	NULL
in	NULL
Current	NULL
Clinical	NULL
Topics	NULL
in	NULL
Infectious	NULL
Diseases	NULL
(	NULL
Remington	NULL
,	NULL
J.	NULL
S.	NULL
,	NULL
&	NULL
Schwartz	NULL
,	NULL
M.	NULL
N.	NULL
,	NULL
eds	NULL
)	NULL
Vol	NULL
.	NULL

2	NULL
,	NULL
pp	NULL
.	NULL

121-150	NULL
,	NULL
McGraw-Hill	NULL
,	NULL
New	NULL
York	NULL
5	NULL
.	NULL

Tuomanen	NULL
,	NULL
E.	NULL
,	NULL
Liu	NULL
,	NULL
H.	NULL
,	NULL
Hengstler	NULL
,	NULL
B.	NULL
,	NULL
Zak	NULL
,	NULL
O	NULL
.	NULL

&	NULL
Tomasz	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

151	NULL
,	NULL
859-868	NULL
6	NULL
.	NULL

Tuomanen	NULL
,	NULL
E.	NULL
,	NULL
Tomasz	NULL
,	NULL
A.	NULL
,	NULL
Hengstler	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Zak	NULL
,	NULL
O	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
J.	NULL
Infect	NULL
.	NULL

Dis	NULL
.	NULL

151	NULL
,	NULL
535-540	NULL
7	NULL
.	NULL

Tuomanen	NULL
,	NULL
E.	NULL
,	NULL
Rich	NULL
,	NULL
R.	NULL
&	NULL
Zak	NULL
,	NULL
O	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Am	NULL
.	NULL

Rev	NULL
.	NULL

Respir	NULL
.	NULL

Dis	NULL
.	NULL

195	NULL
,	NULL
869-874	NULL
2	NULL
W.	NULL
H.	NULL
A.	NULL
Dokter	NULL
,	NULL
A.	NULL
J.	NULL
Dijkstra	NULL
,	NULL
S.	NULL
B.	NULL
Koopmans	NULL
,	NULL
B.	NULL
K.	NULL
Stulp	NULL
,	NULL
W.	NULL
Keck	NULL
,	NULL
M.	NULL
R.	NULL
Halie	NULL
,	NULL
and	NULL
E.	NULL
Vellenga	NULL
,	NULL
unpublished	NULL
results	NULL
.	NULL

9	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

G	NULL
(	NULL
Anh	NULL
)	NULL
MTetra	NULL
Induces	NULL
IL-1B	NULL
and	NULL
IL-6	NULL
Expression	NULL
8	NULL
.	NULL

Riesenfield-Orn	NULL
,	NULL
I.	NULL
,	NULL
Wolpe	NULL
,	NULL
S.	NULL
,	NULL
Garcia-Bustos	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Hoffmann	NULL
,	NULL
M.	NULL
K.	NULL
&	NULL
Tuomanen	NULL
,	NULL
E.	NULL
(	NULL
1989	NULL
)	NULL
Infect	NULL
.	NULL

Immun	NULL
.	NULL

57	NULL
,	NULL
1890-1893	NULL
Tufano	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Cipollare	NULL
de	NULL
I'Ero	NULL
,	NULL
G.	NULL
,	NULL
Ianniello	NULL
,	NULL
R.	NULL
,	NULL
Galdiero	NULL
,	NULL
M.	NULL
&	NULL
Galdiero	NULL
,	NULL
F.	NULL
(	NULL
1991	NULL
)	NULL
Eur	NULL
.	NULL

Cyt	NULL
.	NULL

Netw	NULL
.	NULL

2	NULL
,	NULL
361-366	NULL
Gold	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Miller	NULL
,	NULL
C.	NULL
L.	NULL
&	NULL
Mishell	NULL
,	NULL
R.	NULL
I	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Infect	NULL
.	NULL

Immun	NULL
.	NULL

49	NULL
,	NULL
731-741	NULL
Elonz	NULL
,	NULL
F.	NULL
,	NULL
Adam	NULL
,	NULL
A.	NULL
,	NULL
Ciobarn	NULL
,	NULL
R.	NULL
&	NULL
Lederer	NULL
,	NULL
E.	NULL
(	NULL
1974	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

59	NULL
,	NULL
1317-1322	NULL
Azuma	NULL
,	NULL
I	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Int	NULL
.	NULL

J.	NULL
Immunopharmacol	NULL
.	NULL

14	NULL
,	NULL
487-496	NULL
Vermeulen	NULL
,	NULL
M.	NULL
W.	NULL
&	NULL
Gray	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1984	NULL
)	NULL
Infect	NULL
.	NULL

Immun	NULL
.	NULL

46	NULL
,	NULL
476-483	NULL
Polanski	NULL
,	NULL
M.	NULL
&	NULL
Gray	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
2706-2713	NULL
Holtje	NULL
,	NULL
J.	NULL
V.	NULL
,	NULL
Mirelman	NULL
,	NULL
D.	NULL
,	NULL
Sharon	NULL
,	NULL
N.	NULL
&	NULL
Schwarz	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1975	NULL
)	NULL
J.	NULL
Bacteriol	NULL
.	NULL

124	NULL
,	NULL
1067-1076	NULL
Engel	NULL
,	NULL
H.	NULL
,	NULL
van	NULL
Leeuwen	NULL
,	NULL
A.	NULL
,	NULL
Dijkstra	NULL
,	NULL
A.	NULL
,	NULL
&	NULL
Keck	NULL
,	NULL
W.	NULL
(	NULL
1992	NULL
)	NULL
Appl	NULL
.	NULL

Microbiol	NULL
.	NULL

Biotechnol	NULL
.	NULL

37	NULL
,	NULL
772-783	NULL
Engel	NULL
,	NULL
H.	NULL
,	NULL
Smink	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
van	NULL
Wijngaarden	NULL
,	NULL
L.	NULL
&	NULL
Keck	NULL
,	NULL
W.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Bacteriol	NULL
.	NULL

174	NULL
,	NULL
6394-6403	NULL
Sinha	NULL
,	NULL
R.	NULL
K.	NULL
&	NULL
Rosenthal	NULL
,	NULL
R.	NULL
S.	NULL
(	NULL
1980	NULL
)	NULL
Infect	NULL
.	NULL

Immun	NULL
.	NULL

29	NULL
,	NULL
914-925	NULL
Martin	NULL
,	NULL
S	NULL
,	NULL
A.	NULL
,	NULL
Rosenthal	NULL
,	NULL
R.	NULL
S.	NULL
&	NULL
Biemann	NULL
,	NULL
K.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

262	NULL
,	NULL
7514-7522	NULL
Cookson	NULL
,	NULL
B.	NULL
T.	NULL
,	NULL
Tyler	NULL
,	NULL
A.	NULL
N.	NULL
&	NULL
Goldman	NULL
,	NULL
W.	NULL
E.	NULL
(	NULL
1989	NULL
)	NULL
Biochemistry	NULL
28	NULL
,	NULL
1744-1749	NULL
Krueger	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Pappenheimer	NULL
,	NULL
J.	NULL
R.	NULL
&	NULL
Karnovsky	NULL
,	NULL
M.	NULL
L.	NULL
(	NULL
1982	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

257	NULL
,	NULL
1664-1669	NULL
Krueger	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Karnovsky	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Martin	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Pappenheimer	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Walter	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Biemann	NULL
,	NULL
K.	NULL
(	NULL
1984	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

259	NULL
,	NULL
12659-12662	NULL
Martin	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Karnovsky	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Krueger	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Pappenheimer	NULL
,	NULL
J.	NULL
R.	NULL
&	NULL
Biemann	NULL
,	NULL
K.	NULL
(	NULL
1984	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

259	NULL
,	NULL
12652-12658	NULL
Krueger	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Rosenthal	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Martin	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Walter	NULL
,	NULL
D.	NULL
,	NULL
Davenne	NULL
,	NULL
D.	NULL
,	NULL
Shoham	NULL
,	NULL
S.	NULL
,	NULL
Kubillus	NULL
,	NULL
L.	NULL
&	NULL
Biemann	NULL
,	NULL
K.	NULL
(	NULL
1987	NULL
)	NULL
Brain	NULL
Res	NULL
.	NULL

408	NULL
,	NULL
249-257	NULL
Dinarello	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

&	NULL
Krueger	NULL
,	NULL
J.	NULL
M.	NULL
(	NULL
1986	NULL
)	NULL
Fed	NULL
.	NULL

Proc	NULL
.	NULL

45	NULL
,	NULL
2545-2548	NULL
Dofferhoff	NULL
,	NULL
A.	NULL
S.	NULL
M.	NULL
,	NULL
Esselink	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
de	NULL
Vries-Hospers	NULL
,	NULL
H.	NULL
G.	NULL
,	NULL
v.	NULL
Zanten	NULL
,	NULL
A.	NULL
,	NULL
Bom	NULL
,	NULL
V.	NULL
J.	NULL
J.	NULL
,	NULL
Weits	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Vellenga	NULL
,	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Antimicrob	NULL
.	NULL

Chemother	NULL
.	NULL

31	NULL
,	NULL
373-384	NULL
Akiyama	NULL
,	NULL
T.	NULL
,	NULL
Ishida	NULL
,	NULL
J.	NULL
,	NULL
Nakagawa	NULL
,	NULL
S.	NULL
,	NULL
Ogawara	NULL
,	NULL
H.	NULL
,	NULL
Watanabe	NULL
,	NULL
S.	NULL
I.	NULL
,	NULL
Itoh	NULL
,	NULL
N.	NULL
,	NULL
Shibuya	NULL
,	NULL
M.	NULL
&	NULL
Fukami	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

262	NULL
,	NULL
5592-5595	NULL
O'Dell	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Kandel	NULL
,	NULL
E.	NULL
R.	NULL
&	NULL
Grant	NULL
,	NULL
S.	NULL
G.	NULL
N.	NULL
(	NULL
1991	NULL
)	NULL
Nature	NULL
3538	NULL
,	NULL
558-560	NULL
Vellenga	NULL
,	NULL
E.	NULL
,	NULL
Rambaldi	NULL
,	NULL
A.	NULL
,	NULL
Ernst	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Ostapoviez	NULL
,	NULL
D.	NULL
&	NULL
Griffin	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Blood	NULL
71	NULL
,	NULL
1529-1532	NULL
Brakenhoff	NULL
,	NULL
J.	NULL
P.	NULL
J.	NULL
,	NULL
Groot	NULL
,	NULL
E.	NULL
R.	NULL
,	NULL
Pannekoek	NULL
,	NULL
H.	NULL
&	NULL
Aarden	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

139	NULL
,	NULL
4116-4121	NULL
Helle	NULL
,	NULL
M.	NULL
,	NULL
Boeije	NULL
,	NULL
L.	NULL
,	NULL
de	NULL
Groot	NULL
,	NULL
E.	NULL
,	NULL
de	NULL
Vos	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Aarden	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
188	NULL
,	NULL
47-56	NULL
Dokter	NULL
,	NULL
W.	NULL
H.	NULL
A.	NULL
,	NULL
Sierdsema	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Esselink	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Halie	NULL
,	NULL
M.	NULL
R.	NULL
&	NULL
Vellenga	NULL
,	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Blood	NULL
81	NULL
,	NULL
35-40	NULL
Sambrook	NULL
,	NULL
J.	NULL
,	NULL
Fritsch	NULL
,	NULL
E.	NULL
F.	NULL
&	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Molecular	NULL
Cloning	NULL
:	NULL
A	NULL
Laboratory	NULL
Manual	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
Laboratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
NY	NULL
Schreiber	NULL
,	NULL
E.	NULL
,	NULL
Matthias	NULL
,	NULL
P.	NULL
,	NULL
Miller	NULL
,	NULL
M.	NULL
M.	NULL
&	NULL
Schaffner	NULL
,	NULL
W.	NULL
(	NULL
1989	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17	NULL
,	NULL
6419	NULL
Clark	NULL
,	NULL
B.	NULL
D.	NULL
,	NULL
Collins	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
Gandy	NULL
,	NULL
M.	NULL
S.	NULL
,	NULL
Webb	NULL
,	NULL
A.	NULL
C.	NULL
&	NULL
Auron	NULL
,	NULL
P.	NULL
E.	NULL
(	NULL
1986	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

14	NULL
,	NULL
7897-7914	NULL
Haegeman	NULL
,	NULL
G.	NULL
,	NULL
Content	NULL
,	NULL
J.	NULL
,	NULL
Volckaert	NULL
,	NULL
G.	NULL
,	NULL
Derynck	NULL
,	NULL
R.	NULL
,	NULL
Tavernier	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Fiers	NULL
,	NULL
W.	NULL
(	NULL
1986	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Biochem	NULL
.	NULL

159	NULL
,	NULL
625-632	NULL
Lee	NULL
,	NULL
W.	NULL
,	NULL
Mitchell	NULL
,	NULL
P.	NULL
&	NULL
Tjian	NULL
,	NULL
R.	NULL
(	NULL
1987	NULL
)	NULL
Cell	NULL
49	NULL
,	NULL
741-752	NULL
Dokter	NULL
,	NULL
W.	NULL
H.	NULL
A.	NULL
,	NULL
Esselink	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Halie	NULL
,	NULL
M.	NULL
R.	NULL
&	NULL
Vellenga	NULL
,	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Blood	NULL
81	NULL
,	NULL
337-343	NULL
Kishimoto	NULL
,	NULL
T.	NULL
(	NULL
1989	NULL
)	NULL
Blood	NULL
74	NULL
,	NULL
1-10	NULL
Dinarello	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Blood	NULL
77	NULL
,	NULL
1627-1652	NULL
Kovacs	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
Brock	NULL
,	NULL
B.	NULL
,	NULL
Varesio	NULL
,	NULL
L.	NULL
&	NULL
Young	NULL
,	NULL
H.	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

1438	NULL
,	NULL
3532-3537	NULL
Schlinder	NULL
,	NULL
R.	NULL
,	NULL
Clark	NULL
,	NULL
B.	NULL
D.	NULL
&	NULL
Dinarello	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
10232-10237	NULL
Fenton	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Clark	NULL
,	NULL
B.	NULL
D.	NULL
,	NULL
Collins	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
Webb	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Rich	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Auron	NULL
,	NULL
P.	NULL
E.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

188	NULL
,	NULL
3972-3979	NULL
Turner	NULL
,	NULL
M.	NULL
,	NULL
Chantry	NULL
,	NULL
D.	NULL
,	NULL
Buchan	NULL
,	NULL
G.	NULL
,	NULL
Barrett	NULL
,	NULL
K.	NULL
&	NULL
Feldmann	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
3556-3561	NULL
De	NULL
Wit	NULL
,	NULL
H.	NULL
,	NULL
Dokter	NULL
,	NULL
W.	NULL
H.	NULL
A.	NULL
,	NULL
Esselink	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
Halie	NULL
,	NULL
M.	NULL
R.	NULL
&	NULL
Vellenga	NULL
,	NULL
E.	NULL
(	NULL
1993	NULL
)	NULL
Exp	NULL
.	NULL

Hematol	NULL
.	NULL

21	NULL
,	NULL
785-790	NULL
Fenton	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Vermeulen	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Clark	NULL
,	NULL
B.	NULL
D.	NULL
,	NULL
Webb	NULL
,	NULL
A.	NULL
C.	NULL
&	NULL
Auron	NULL
,	NULL
P.	NULL
E.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

140	NULL
,	NULL
2267-2273	NULL
Bduerie	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
58	NULL
,	NULL
211-217	NULL
Ghosh	NULL
,	NULL
S.	NULL
&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Nature	NULL
344	NULL
,	NULL
678-682	NULL
Lieberman	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
,	NULL
2327-2334	NULL
Shimizu	NULL
,	NULL
H.	NULL
,	NULL
Mitomo	NULL
,	NULL
K.	NULL
,	NULL
Watanabe	NULL
,	NULL
T.	NULL
,	NULL
Okamoto	NULL
,	NULL
S.	NULL
&	NULL
Yamamoto	NULL
,	NULL
K.-I	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
,	NULL
561-568	NULL
Brach	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
de	NULL
Vos	NULL
,	NULL
S.	NULL
,	NULL
Arnold	NULL
,	NULL
C.	NULL
,	NULL
Grug	NULL
,	NULL
H.	NULL
J	NULL
,	NULL
Mertelsmann	NULL
,	NULL
R.	NULL
&	NULL
Hermann	NULL
,	NULL
F.	NULL
(	NULL
1992	NULL
)	NULL
Eur	NULL
J.	NULL
Immunol	NULL
.	NULL

22	NULL
,	NULL
2705-2711	NULL
Gruss	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
Brach	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

&	NULL
Herrmann	NULL
,	NULL
F.	NULL
(	NULL
1992	NULL
)	NULL
Blood	NULL
80	NULL
,	NULL
2563-2570	NULL
Chauhan	NULL
,	NULL
D.	NULL
,	NULL
Kharbanda	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Rubin	NULL
,	NULL
E.	NULL
,	NULL
Barut	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Mohrbacher	NULL
,	NULL
A.	NULL
,	NULL
Kufe	NULL
,	NULL
D.	NULL
W.	NULL
&	NULL
Anderson	NULL
,	NULL
K.	NULL
C.	NULL
(	NULL
1993	NULL
)	NULL
Blood	NULL
81	NULL
,	NULL
1540-1548	NULL
Dziarski	NULL
,	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
4713-4718	NULL
Dziarski	NULL
,	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

266	NULL
,	NULL
4719-4725	NULL
Le	NULL
Contel	NULL
,	NULL
C.	NULL
,	NULL
Temime	NULL
,	NULL
N.	NULL
,	NULL
Charron	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

&	NULL
Parant	NULL
,	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

150	NULL
,	NULL
4541-4549	NULL
Holte	NULL
,	NULL
J.	NULL
V.	NULL
&	NULL
Tuomanen	NULL
,	NULL
E.	NULL
I	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Gen.	NULL
Microbiol	NULL
.	NULL

187	NULL
,	NULL
441-454	NULL

